Keros Therapeutics

KROSNASDAQHigh Risk

Keros develops small molecules that modulate TGF-beta signaling, specifically targeting ALK2 and ALK5 receptors to treat diseases of low blood cell counts and muscle loss.

Reviewed by Blane Jackson, DDS, MBA. Educational analysis only. Read the editorial policy and disclosures.

Rare & Orphan Diseases Hematology Musculoskeletal Diseases

Market cap

Small cap

Cash position

$247M as of Q3 2025

~30 months runway (derived)

Revenue status

pre revenue

Pipeline assets

3 programs

Trade KROS commission-free on Webullvia Webull · Affiliate

What does Keros Therapeutics do?

Keros Therapeutics is a biotech company that is trying to develop new medicines for rare diseases, which are conditions that affect a small number of people. They are focusing on two main areas: diseases where the body doesn't make enough blood cells, and diseases that cause muscle loss. Their most advanced drug is called KER-065, which is being tested in patients with Duchenne Muscular Dystrophy, a severe genetic disease that causes muscle weakness and usually affects boys. KER-065 works by blocking certain signals in the body that tell muscles to waste away. This is different from other treatments like gene therapy, which aim to fix the underlying genetic problem. Keros has had some setbacks with other drugs, but they have a lot of money to keep going. For investors, the big question is whether KER-065 will work in clinical trials. If it does, it could be a big deal because there is a huge need for better treatments for DMD. But there are risks: the trials might fail, or other companies might come up with better treatments. Overall, Keros is a high-risk, high-reward investment opportunity.

What to watch

Monitor enrollment and any early data from the KER-065 Phase 2 trial in DMD.

Watch for any announcements about partnerships or licensing deals for KER-065.

Track cash burn and any secondary offerings to assess dilution risk.

Pipeline

Drug	Indication	Phase	Expected data
KER-065	Duchenne Muscular Dystrophy	Phase 2	2027	▼
KER-012	Pulmonary Arterial Hypertension	Phase 2	Terminated	▼
KER-047	Iron Deficiency Anemia	Phase 2	Withdrawn	▼

Investment thesis

Bull case

Keros has a promising pipeline targeting rare diseases with high unmet need. Its lead candidate, KER-065, for Duchenne Muscular Dystrophy, could address a significant market if successful. The company's platform targeting TGF-beta signaling is versatile and could yield multiple drugs. With a strong cash position and no debt, Keros is well-funded to advance its pipeline. The recent termination of KER-012 in PAH may actually be a positive, allowing focus on higher-potential programs. If KER-065 shows efficacy in Phase 2, it could become a standard of care, and the stock could multiply.

Bear case

Keros has faced setbacks with KER-012 and KER-047, raising concerns about the platform's viability. The DMD trial is still early, and competition from gene therapies like Elevidys may limit market share. The company is pre-revenue and will need to raise capital, potentially diluting shareholders. Regulatory hurdles for rare disease drugs are high, and reimbursement uncertainties could impact commercial success. The small patient population for DMD means even a successful launch may not generate blockbuster revenues. Additionally, the termination of KER-012 may indicate underlying safety issues with the platform.

Key upcoming catalysts

Initiation of Phase 2 trial for KER-065 in DMD

Q1 2026

Unverified — this date has not been checked against a primary source.

Data ReadoutSignificant

Interim data from KER-065 trial

2027

Unverified — this date has not been checked against a primary source.

Data ReadoutStock moving

Potential partnership for KER-065

2026

Unverified — this date has not been checked against a primary source.

ConferenceSignificant

Risk factors

⚠

Clinical trial failure: KER-065 may not show efficacy or safety in DMD.

⚠

Competition: Sarepta's Elevidys and other DMD therapies may dominate the market.

⚠

Regulatory uncertainty: FDA may require additional trials or have concerns about the mechanism.

⚠

Financial risk: Cash runway may be insufficient if trials are delayed, leading to dilution.

⚠

Platform risk: Setbacks in other programs may indicate broader issues with the technology.

Chart KROS on TradingView — used by 30M+ tradersvia TradingView · Affiliate

Comparable companies

SRPT BMRNUTX

Financial snapshot

These figures are drafted by our AI pipeline, not read from SEC filings. Confirm anything you would act on against the company's latest 10-Q or 10-K.

Cash

$247M as of Q3 2025

Q3 2025 — 4 quarters ago

Quarterly burn

$25M

Cash runway

~30 months

$247M ÷ $25M per quarter

Revenue

pre revenue

Institutional ownership

85%

Source: company profile text. These figures come from the company profile text, not from a filing we have parsed. Check them against the latest 10-Q before relying on them.

These figures are out of date

The cash position cited here is from Q3 2025, roughly 4 quarters ago. The company has almost certainly reported since. Check its latest filing before using any of this.

Cash against the next catalyst

Tight against cash

Cash reaches roughly Q1 2028 on the disclosed figures, about 4 quarters past this Q1 2027 catalyst. A disappointing result would leave little room to fund what comes next.

Derived from $247M ÷ $25M per quarter, both self-reported.
Burn usually rises as a programme moves through late-stage trials, so this is an upper bound.
The cash figure is from Q3 2025, about 4 quarters ago. The company has almost certainly reported since.

This is the arithmetic between two dates, not a forecast. Companies raise early from strength, delay programmes, partner, or borrow.